Total funding activity continues to show YoY rise. Significant acquisition activity in the sector.

2. Genomics Report – November 2016
Tracxn
World’s Largest Startup Research Platform
2

3. Genomics Report – November 20163
Contents
Topic Page No.
Scope of Report 04
Entrepreneur Activity 06
Investment Trend 08
Who is Investing 19
Exit Outlook - IPO, Acquisitions 23
Sub Sector Analysis 27
Interesting Companies 46
Company List 54
Team 143

4. Genomics Report – November 20164
Sector Overview
Scope of report
The report includes companies which are providing products and services for high-throughput sequencing; developing
sequencing technologies; developing tools (or softwares) and providing services for sequencing data analysis; providing
diagnostic products and services that use high-throughput sequencing to assess the risk of development of disease in
asymptomatic individuals, detect presence of a disease/condition, or to determine best treatment regimens for diagnosed
patients.
We have excluded clinical laboratories that provides sequencing services for diagnostics without their own proprietary
technology.
The scope of this report includes equity as well as debt funding received by the companies.

5. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
5

6. Genomics Report – November 2016
39
54
64
70
79
49
10
0
18
36
54
72
90
2010 2011 2012 2013 2014 2015 2016
NumberofCompanies
6
YoY – Number of companies founded
Foundation Medicine Personalis Guardant Health Human Longevity Inivata iCarbonX Grail Bio
Med fusion Fulgent Diagnostics Invitae Color Genomics Arivale Helix ReadCoor

7. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
7

8. Genomics Report – November 20168
YoY – Number of Rounds and Total Funding
Note: The funding includes debt rounds also.
$146M
$327M
$646M
$373M
$560M $536M
$1.5B
$1.6B
$1.7B
25
45
53
44
76 76
89
113
91
0
24
48
72
96
120
0
360
720
1080
1440
1800
2008 2009 2010 2011 2012 2013 2014 2015 2016
NumberofRounds
FundingAmount(inMillions)
Funding Amount Number of Rounds

9. Genomics Report – November 20169
YoY – Number of Rounds by Stage
7
22 24 23
39
19
25
34 33
46
47
56
12
16 16
17
19
13
0
24
48
72
96
120
2011 2012 2013 2014 2015 2016
NumberofRounds
Seed Early Late

10. Genomics Report – November 201610
YoY – Funding by Stage
$6M $16M $17M $24M $35M $17M
$171M
$255M
$193M
$875M
$603M
$1.3B
$195M
$279M $322M
$438M
$727M
$414M
0
400
800
1200
1600
2000
2011 2012 2013 2014 2015 2016
TotalFundingAmount(inMillions)
Seed Early Late

11. Genomics Report – November 201611
Average Ticket Size – Early Stage
$0.9M $0.9M $0.8M
$1.3M $1.1M $0.9M
$6.7M
$5.5M $4.0M
$7.8M
$13.0M
$23.5M
$8.4M $8.6M
$8.0M
$45.7M
$17.6M
$29.1M
0.0
10.0
20.0
30.0
40.0
50.0
2011 2012 2013 2014 2015 2016
FundingAmount(inMillions)
Seed Series A Series B

12. Genomics Report – November 201612
Top investments in last one year (1/5)
Company
Funding
Amount
Round
Name
Date Investors
humanlongevity.com
Human Longevity
(San Diego, 2013)
$220M Series B Apr-2016 GE Ventures, Illumina, Celgene
icarbonx.com
iCarbonX
(Shenzhen, 2015)
$155M Series A Apr-2016 Zhongyuan Union Stem Cell Bioengineering, Tencent
23andme.com
23andMe
(Mountain View,
2006)
$115M Series E Oct-2015
Fidelity Investments, WuXi Healthcare Ventures, Casdin Capital, Illumina, NEA, MPM
Capital, GV, Xfund
grailbio.com
Grail Bio
(San Diego, 2016)
$100M Series A Jan-2016 Illumina, ARCH Venture Partners, Sutter Hill Ventures, Bezos Expeditions
guardanthealth.com
Guardant Health
(Redwood City, 2012)
$100M Series D Jan-2016
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar
Ventures, Formation 8, Heritage Group
lasergen.com
Lasergen
(Houston, 2002)
$80M PE Mar-2016 Agilent
codiakbio.com
Codiak BioSciences
(Woburn, 2015)
$61M Series B Jan-2016
Flagship Ventures, ARCH Venture Partners, Alexandria Real Estate Equities, Fidelity
Investments

13. Genomics Report – November 201613
Top investments in last one year (2/5)
Company
Funding
Amount
Round
Name
Date Investors
10xgenomics.com
10X Genomics
(Pleasanton, 2012)
$55M Series C Mar-2016 Paladin Capital Group, SoftBank, Fidelity Investments, Foresite Capital, Venrock
nanthealth.com
NantHealth
(Culver City, 2007)
$53M Series C Jan-2016
getcolor.com
Color Genomics
(Burlingame, 2013)
$45M Series B Sep-2016 General Catalyst Partners, 8VC, Khosla Ventures, 8VC
inivata.com
Inivata
(Cambridge, 2014)
$45M Series A Jan-2016
Imperial Innovations, Cambridge Capital Group, JJDC, Woodford Investment
Management
sbgenomics.com
Seven Bridges
Genomics
(Cambridge, 2009)
$45M Series A Feb-2016
icarbonx.com
iCarbonX
(Shenzhen, 2015)
$45M Series A Jul-2016 China Bridge Capital
accuragen.com
AccuraGen
(Menlo Park, 2013)
$40M Series B Jun-2016 Decheng Capital, Temasek, DT Capital Partners, StartX, Nan Fung Group
pathway.com
Pathway Genomics
(San Diego, 2008)
$40M Series E Jan-2016 IBM Watson

14. Genomics Report – November 201614
Top investments in last one year (3/5)
Company
Funding
Amount
Round
Name
Date Investors
codiakbio.com
Codiak BioSciences
(Woburn, 2015)
$31M Series A Nov-2015
ARCH Venture Partners, Fidelity Investments, Alexandria Real Estate Equities, Flagship
Ventures
veritasgenetics.com
Veritas Genetics
(Danvers, 2014)
$30M Series B Oct-2016 Lilly Asia Ventures, Trustbridge Partners, Simcere Pharma
fulgentdiagnostics.com
Fulgent Diagnostics
(Temple City, 2011)
$27M Series A May-2016
centrilliontech.com
Centrillion
Technologies
(Palo Alto, 2009)
$27M Series C May-2016
syapse.com
Syapse
(Palo Alto, 2008)
$25M Series C Jan-2016 Ascension Ventures, Social Capital, Safeguard Scientifics
omicia.com
Omicia
(Oakland, 2009)
$23M Series B Jun-2016 UPMC, Roche, LDV Partners, Ping An Ventures, ARTIS Ventures
readcoor.com
ReadCoor
(Cambridge, 2016)
$23M Series A Sep-2016 Decheng Capital, Lilly Asia Ventures, Vivo Capital
biodesix.com
Biodesix
(Broomfield, 2005)
$22M Series F Feb-2016

15. Genomics Report – November 201615
Top investments in last one year (4/5)
Company
Funding
Amount
Round
Name
Date Investors
personalgenome.com
Personal Genome
(Baltimore, 2010)
$21M Series A Oct-2015 NEA, Windham Venture Partners
cambridge-epigenetix.com
Cambridge Epigenetix
(Cambridge, 2012)
$21M Series B Mar-2016 GV, Sequoia Capital, Syncona Partners, New Science Ventures, University of Cambridge
genomind.com
Genomind
(King Of Prussia,
2009)
$21M Series A Jul-2016 Claritas Capital
singleragenomics.com
Singlera Genomics
(La Jolla, 2014)
$20M Series A Aug-2016 Lilly Asia Ventures, Green Pine Capital Partners, CDBI Partners
purigenbio.com
Purigen Biosystems
(Pleasanton, 2012)
$18M Series A May-2016 5AM Ventures, Roche, StartX
pillar-biosciences.com
Pillar Biosciences
(Natick, 2013)
$18M Series A May-2016
enterome.fr
Enterome
(Paris, 2012)
$17M Series C Apr-2016 Seventure Partners, Lundbeckfond Ventures, Nestle Health Science
exosomedx.com
Exosome Diagnostics
(New York City, 2008)
$15M Series B Jan-2016

16. Genomics Report – November 201616
Top investments in last one year (5/5)
Company
Funding
Amount
Round
Name
Date Investors
icarbonx.com
iCarbonX
(Shenzhen, 2015)
$15M Series A Jan-2016 Zhongyuan Union Stem Cell Bioengineering
assurexhealth.com
Assurex Health
(Mason, 2006)
$15M Series D Dec-2015
Sequoia Capital, Mayo Clinic, Claremont Creek Ventures, Cincinnati Childrens Hospital
Medical Center, Cross Creek Advisors
clinicalgenomics.com
Clinical Genomics
(Sydney, 2006)
$15M Series A Mar-2016 One Ventures
sophiagenetics.com
Sophia Genetics
(Lausanne, 2011)
$15M Series C Dec-2015
caredxinc.com
CareDx
(Brisbane, 2000)
$14M PE Apr-2016
actgenomics.com
ACT Genomics
(Taipei, 2014)
$13M Series B May-2016 Hotung Group, China Development Financial Holding, pidc.com.tw, UMC Capital
strataoncology.com
Strata Oncology
(Ann Arbor, 2015)
$12M Series A Jun-2016 Arboretum Ventures, Baird Capital, eLab Ventures
bluebee.com
Bluebee
(Delft, 2011)
$11M Series A Mar-2016 Capricorn Venture Partners, Korys, Buysse & Partners

17. Genomics Report – November 201617
Funnel view of Sector
Percent of
Previous
67%
58%
45%
88
58
112
249
428
642
0 140 280 420 560 700
M&A & IPO
Late
Series B
Series A
Funded
Founded
Number of Companies

18. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
18

19. Genomics Report – November 201619
Most Active Investors in Sector
8 8 8
7 7
6 6
5 5 5
0
2
4
5
7
9
Mohr Davidow
Ventures
Orbimed Sequoia
Capital
ARCH Venture
Partners
Illumina KPCB Sutter Hill
Ventures
Casdin
Capital
IndieBio Roche
TotalNumberofRounds
Pacific
Biosciences
Guardant Health Guardant Health Illumina
Oxford Nanopore
Technologies
Pacific
Biosciences
Pacific
Biosciences
Adaptive
Biotechnologies
Ranomics
Foundation
Medicine
23andMe Invitae Natera Grail Bio
Adaptive
Biotechnologies
CareDx Illumina 23andMe Girihlet
Stratos
Genomics

20. Genomics Report – November 201620
Where are Top Investors investing

21. Genomics Report – November 201621
Top Investor by Stage of Entry

22. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
22

23. Genomics Report – November 201623
Top IPOs in last three years
IPO Date Company Overview
Funding
Amount
Ticker
Jun-2016 nanthealth.com
NantHealth
(Culver City, 2007)
Combining medical data and patients' genetic information to find individualized
treatment for cancer and other diseases
Blackberry, Blackstone, Verizon, Allscripts, Celgene, Kuwait Investment Authority
$765M NH
Nov-2015 oncovista.com
OncoVista
(San Antonio, 2004)
Develops therapeutics and diagnostics for cancer.
Chicago Venture Partners $65M OVIT
Jun-2015 natera.com
Natera
(Redwood City, 2004)
Diagnostics company specializing in prenatal and pre-implantation diagnostics.
Lightspeed Venture Partners, Sequoia Capital, Orbimed, Founders Fund,
Sofinnova Ventures, Harmony Partners, Claremont Creek Ventures, RA Capital
Management, Alafi Capital, Jennison Associates, Franklin Templeton, HRC
Fertility, Capital Group, Claremont Creek Ventures, HealthCor Partners
$152.1M NTRA
Feb-2015 invitae.com
Invitae
(San Francisco, 2012)
A genetic information company.
Orbimed, Casdin Capital, Thomas, The Broe Group, Decheng Capital, Deerfield,
Genesys Capital, Genomic Health, Wellington Management, Rock Springs Capital,
Redmile Group, Perceptive Advisors
$189.56M NVTA
Jul-2014 caredxinc.com
CareDx
(Brisbane, 2000)
Predicting risk of transplant rejection for heart transplant patients.
KPCB, Intel Capital, Silicon Valley Bank, Integral Capital Partners, TPG Growth,
Duff Ackerman & Goodrich, Burrill and Company, New Leaf Ventures, Sprout
Group, TPG, Double Bottom Line Investors, Oxford Finance, Leader Ventures,
Bristol-Myers Squibb, gehealthcarefinance.com, DBL Partners
$114.82M CDNA
Nov-2013 veracyte.com
Veracyte
(San Francisco, 2008)
Genomic solutions for cancer diagnostics
KPCB, TPG, Versant Ventures, Domain Associates, GE Ventures $95.65M VCYT

24. Genomics Report – November 201624
Major Acquisitions in last one year (1/2)

25. Genomics Report – November 201625
Major Acquisitions in last one year (2/2)

26. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
26

27. Genomics Report – November 201627
October 2016Tracxn BlueBox : Biotech
4800+ companies in the sector, 2369 funded in last 5 years, over $18.6B invested since ‘15

28. Genomics Report – November 201628
October 2016Tracxn BlueBox : Diagnostics (Tech)
1720+ companies in the sector, 810 funded in last 5 years, $4.8B+ invested in 2015/16

29. Genomics Report – November 201629
Top Business Models by Funding
$2.0B
$1.8B
$1.5B
$1.3B
$1.0B
$0.7B
0.0
0.5
1.0
1.5
2.0
2.5
Clinical Genomics Bioinformatics Sequencing Technology Genetic Testing Liquid Biopsy Research Genomics
TotalFundingAmount(inBillions)
# Cos. 196 193 31 82 53 87
Avg. Age Jan-09 Apr-09 Apr-07 Jan-09 Jul-09 Nov-06
Adaptive Biotechnologies NantHealth Oxford Nanopore Technologies 23andMe Guardant Health 10X Genomics
CareDx Human Longevity Pacific Biosciences Invitae Biodesix RainDance Tech

30. Genomics Report – November 201630
Clinical Genomics – Business Model Description

31. Genomics Report – November 201631
Clinical Genomics – Entrepreneur Activity and
Investment Trend

32. Genomics Report – November 201632
Clinical Genomics – Most Funded Companies

33. Genomics Report – November 201633
Bioinformatics – Business Model Description

34. Genomics Report – November 201634
Bioinformatics – Entrepreneur Activity and
Investment Trend

35. Genomics Report – November 201635
Bioinformatics – Most Funded Companies

36. Genomics Report – November 201636
Sequencing Technology – Business Model
Description

37. Genomics Report – November 201637
Sequencing Technology – Entrepreneur Activity
and Investment Trend

38. Genomics Report – November 201638
Sequencing Technology – Most Funded Companies

39. Genomics Report – November 201639
Genetic Testing – Business Model Description

40. Genomics Report – November 201640
Genetic Testing – Entrepreneur Activity and
Investment Trend

41. Genomics Report – November 201641
Genetic Testing – Most Funded Companies

42. Genomics Report – November 201642
Liquid Biopsy – Business Model Description

43. Genomics Report – November 201643
Liquid Biopsy – Entrepreneur Activity and
Investment Trend

44. Genomics Report – November 201644
Liquid Biopsy – Most Funded Companies

45. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
45

46. Genomics Report – November 201646
Interesting Unfunded Companies
Company Overview Business Model
tempus.com
Tempus
(2015, Chicago)
Oncology platform for sequencing, analytics and informatics
Bioinformatics > Clinical Informatics
avatardss.com
Avatar DSS
(2015, Tampa)
Precision treatment support for cancer patients Bioinformatics > Clinical Informatics >
Pharmacogenomics
Vital Genomics
(2015, Boca Raton)
Provide physicians with pharmacogenomics technology, training, educational
support, and patient communications
Clinical Genomics > Pharmacogenomics
Saga Diagnostics
(2016, Lund)
Tests for detection and analysis of circulating tumor DNA Liquid Biopsy
Lifenome
(2015, NYC)
Genomics-driven personal wellness Genetic Testing > Nutrigenomics
Curated list of companies by the sector analyst are defined as Interesting

47. Genomics Report – November 201647
Interesting Seed Companies

48. Genomics Report – November 201648
Interesting Series A Companies

49. Genomics Report – November 201649
Interesting Series B Companies

50. Genomics Report – November 201650
Interesting Late Stage Companies

51. Genomics Report – November 201651
Interesting Late Stage Companies

52. Genomics Report – November 201652
Top Funded Deadpooled Companies

53. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
53

54. Genomics Report – November 201654

55. Genomics Report – November 201655
Genomics – Company List
Clinical Genomics Bioinformatics
Sequencing
Technology
Genetic Testing Liquid Biopsy
Research
Genomics
428 FUNDED COMPANIES AND 214 UNFUNDED COMPANIES
COVERS THE FOLLOWING SECTORS

56. Genomics Report – November 201656
Clinical Genomics (1/26)
Company Overview Business Model Total Funding
MDxHealth
(2003, Irvine)
Epigenetic tests for personalized cancer assessment and treatment.
Seventure Partners, Idinvest Partners, IWT, EuroTransBio, IPSA Epigenetics $94.14M
Epigenomics
(1998, Berlin)
Molecular Diagnostics for Cancer
Wellcome Trust, 3i Group, MPM Capital, Abingworth, DVCG, BioChain,
Creathor Venture, European Commission
Epigenetics $52.05M
OncoMethylome
(2003, Antwerp)
Diagnostics for early detection of cancer
Epigenetics $16M
Nucleix
(2008, Rehovot)
Develops non-invasive molecular cancer diagnostic tests
Orbimed, Aurum Ventures Epigenetics $11.5M
Oxford Biodynamics
(2007, Oxford)
Biomarker discovery based on epigenetics for personalized diagnostics.
Epigenetics $11M
MetaStat
(2007, Montclair)
Develops and commercializes diagnostic tests for the prediction of
cancer metastasis.
H.C. Wainwright
Epigenetics $1.5M
Oncgnostics
(2012, Jena)
Develops epigenetic biomarkers diagnostic tests
High-Tech Grunderfonds, Bm-t Beteiligungsmanagement Thuringen,
Sparkasse Jena Saale Holzland, STIFT
Epigenetics
Episona
(2013, Los Angeles)
Test kit using epigenetics to test male infertility.
Epigenetics
Go to BM List >> Bioinformatics

57. Genomics Report – November 201657
Clinical Genomics (2/26)
Company Overview Business Model Total Funding
RiboMed Biotechnologies
(1999, Carlsbad)
Personalized diagnostics, prognostics and theranostics based on
epigenetics. Epigenetics
PrognosDx Health
(2008, Palo Alto)
Epigenetic testing technology to identify cancer
Epigenetics
Behavioral Diagnostics
(2009, Iowa City)
Epigenetics based substance use diagnostics
National Institutes of Health Epigenetics
Adaptive Biotechnologies
(2009, Seattle)
Engages in immune-based discoveries and diagnostics by combining
high-throughput sequencing & bioinformatics to profile immune cell
receptors genes.
Illumina, Tiger Global Management, Matrix Partners, Casdin Capital,
Celgene, Alexandria Real Estate Equities, BD Biosciences, Foresite
Capital, Laboratory Corporation of America, Rock Springs Capital, Viking
Global Investors, Senator Investment, National Heart Lung and Blood
Institute
Immunosequencing $404.35M
Sequenta
(2008, San Francisco)
Immunesequencing for blood cancers
Index Ventures, Mohr Davidow Ventures, Celgene, Foresite Capital Immunosequencing $43.46M
Repertoire
(2014, Ibaraki)
TCR/BCR repertoire analysis services
The University of Tokyo Edge Capital, Beyond Next Ventures Immunosequencing $6.47M
MIODx
(2014, San Jose)
Diagnostics based on genomics and immunesequencing.
Immunosequencing $1.5M
Go to BM List >> Bioinformatics

58. Genomics Report – November 201658
Clinical Genomics (3/26)
Company Overview Business Model Total Funding
ImmunID
(2005, Grenoble)
Molecular diagnostics using immune profiling
Immunosequencing
Enterome
(2012, Paris)
Therapeutic solutions for diseases associated with abnormalities of the
gut microbiome (such as Inflammatory Bowel Diseases).
Omnes Capital, Seventure Partners, Lundbeckfond Ventures, INRA
Transfert, Lundbeckfonden, Nestle Health Science
Microbiomics $39.16M
uBiome
(2012, San Francisco)
Citizen science startup to sequence the human microbiome.
Andreessen Horowitz, 500 Startups, Kapor Capital, Bansea, Linden
Mobile Ventures, Three Bridges Venture Partners, Milliways Ventures,
BoxGroup
Microbiomics $4.97M
GoodGut
(2014, Girona)
Diagnosis and treatment of digestive diseases based on intestinal
microbiota analysis
Caixa Capital Risc, BAGi
Microbiomics $852.5k
IS-Diagnostics
(2011, Amsterdam)
Provider of technology that enables the diagnosis, ongoing tracking and
management of bacterial populations in various habitats. Microbiomics
OmniBiome
(2012, San Diego)
Diagnostics, therapeutics for pregnancy-associated conditions where
there is a substantive link with microbiome / microbiota dysbiosis. Microbiomics
Quantibio
(2014, Beijing)
Focuses on the gene mapping of human gut microbiome
Globals Tech. Microbiomics
Go to BM List >> Bioinformatics

59. Genomics Report – November 201659
Clinical Genomics (4/26)
Go to BM List >> Bioinformatics

60. Genomics Report – November 201660
Clinical Genomics (5/26)
Go to BM List >> Bioinformatics

61. Genomics Report – November 201661
Clinical Genomics (6/26)
Go to BM List >> Bioinformatics

62. Genomics Report – November 201662
Clinical Genomics (7/26)
Go to BM List >> Bioinformatics

63. Genomics Report – November 201663
Clinical Genomics (8/26)
Go to BM List >> Bioinformatics

64. Genomics Report – November 201664
Clinical Genomics (9/26)
Go to BM List >> Bioinformatics

65. Genomics Report – November 201665
Clinical Genomics (10/26)
Go to BM List >> Bioinformatics

66. Genomics Report – November 201666
Clinical Genomics (11/26)
Go to BM List >> Bioinformatics

67. Genomics Report – November 201667
Clinical Genomics (12/26)
Go to BM List >> Bioinformatics

68. Genomics Report – November 201668
Clinical Genomics (13/26)
Go to BM List >> Bioinformatics

69. Genomics Report – November 201669
Clinical Genomics (14/26)
Go to BM List >> Bioinformatics

70. Genomics Report – November 201670
Clinical Genomics (15/26)
Go to BM List >> Bioinformatics

71. Genomics Report – November 201671
Clinical Genomics (16/26)
Go to BM List >> Bioinformatics

72. Genomics Report – November 201672
Clinical Genomics (17/26)
Go to BM List >> Bioinformatics

73. Genomics Report – November 201673
Clinical Genomics (18/26)
Go to BM List >> Bioinformatics

74. Genomics Report – November 201674
Clinical Genomics (19/26)
Go to BM List >> Bioinformatics

75. Genomics Report – November 201675
Clinical Genomics (20/26)
Go to BM List >> Bioinformatics

76. Genomics Report – November 201676
Clinical Genomics (21/26)
Go to BM List >> Bioinformatics

77. Genomics Report – November 201677
Clinical Genomics (22/26)
Go to BM List >> Bioinformatics

78. Genomics Report – November 201678
Clinical Genomics (23/26)
Go to BM List >> Bioinformatics

79. Genomics Report – November 201679
Clinical Genomics (24/26)
Go to BM List >> Bioinformatics

80. Genomics Report – November 201680
Clinical Genomics (25/26)
Go to BM List >> Bioinformatics

81. Genomics Report – November 201681
Clinical Genomics (26/26)
Go to BM List >> Bioinformatics

82. Genomics Report – November 201682
Bioinformatics (1/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

83. Genomics Report – November 201683
Bioinformatics (2/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

84. Genomics Report – November 201684
Bioinformatics (3/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

85. Genomics Report – November 201685
Bioinformatics (4/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

86. Genomics Report – November 201686
Bioinformatics (5/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

87. Genomics Report – November 201687
Bioinformatics (6/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

88. Genomics Report – November 201688
Bioinformatics (7/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

89. Genomics Report – November 201689
Bioinformatics (8/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

90. Genomics Report – November 201690
Bioinformatics (9/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

91. Genomics Report – November 201691
Bioinformatics (10/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

92. Genomics Report – November 201692
Bioinformatics (11/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

93. Genomics Report – November 201693
Bioinformatics (12/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

94. Genomics Report – November 201694
Bioinformatics (13/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

95. Genomics Report – November 201695
Bioinformatics (14/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

96. Genomics Report – November 201696
Bioinformatics (15/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

97. Genomics Report – November 201697
Bioinformatics (16/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

98. Genomics Report – November 201698
Bioinformatics (17/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

99. Genomics Report – November 201699
Bioinformatics (18/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

100. Genomics Report – November 2016100
Bioinformatics (19/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

101. Genomics Report – November 2016101
Bioinformatics (20/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

102. Genomics Report – November 2016102
Bioinformatics (21/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

103. Genomics Report – November 2016103
Bioinformatics (22/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

104. Genomics Report – November 2016104
Bioinformatics (23/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

105. Genomics Report – November 2016105
Bioinformatics (24/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

106. Genomics Report – November 2016106
Bioinformatics (25/25)
Clinical
Genomics
<< Go to BM List >>
Sequencing
Technology

107. Genomics Report – November 2016107
Sequencing Technology (1/5)
Bioinformatics << Go to BM List >> Genetic Testing

108. Genomics Report – November 2016108
Sequencing Technology (2/5)
Bioinformatics << Go to BM List >> Genetic Testing

109. Genomics Report – November 2016109
Sequencing Technology (3/5)
Bioinformatics << Go to BM List >> Genetic Testing

110. Genomics Report – November 2016110
Sequencing Technology (4/5)
Bioinformatics << Go to BM List >> Genetic Testing

111. Genomics Report – November 2016111
Sequencing Technology (5/5)
Bioinformatics << Go to BM List >> Genetic Testing

112. Genomics Report – November 2016112
Genetic Testing (1/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

113. Genomics Report – November 2016113
Genetic Testing (2/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

114. Genomics Report – November 2016114
Genetic Testing (3/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

115. Genomics Report – November 2016115
Genetic Testing (4/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

116. Genomics Report – November 2016116
Genetic Testing (5/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

117. Genomics Report – November 2016117
Genetic Testing (6/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

118. Genomics Report – November 2016118
Genetic Testing (7/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

119. Genomics Report – November 2016119
Genetic Testing (8/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

120. Genomics Report – November 2016120
Genetic Testing (9/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

121. Genomics Report – November 2016121
Genetic Testing (10/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

122. Genomics Report – November 2016122
Genetic Testing (11/11)
Sequencing
Technology
<< Go to BM List >> Liquid Biopsy

123. Genomics Report – November 2016123
Liquid Biopsy (1/7)
Genetic Testing << Go to BM List >>
Research
Genomics

124. Genomics Report – November 2016124
Liquid Biopsy (2/7)
Genetic Testing << Go to BM List >>
Research
Genomics

125. Genomics Report – November 2016125
Liquid Biopsy (3/7)
Genetic Testing << Go to BM List >>
Research
Genomics

126. Genomics Report – November 2016126
Liquid Biopsy (4/7)
Genetic Testing << Go to BM List >>
Research
Genomics

127. Genomics Report – November 2016127
Liquid Biopsy (5/7)
Genetic Testing << Go to BM List >>
Research
Genomics

128. Genomics Report – November 2016128
Liquid Biopsy (6/7)
Genetic Testing << Go to BM List >>
Research
Genomics

129. Genomics Report – November 2016129
Liquid Biopsy (7/7)
Genetic Testing << Go to BM List >>
Research
Genomics

130. Genomics Report – November 2016130
Research Genomics (1/12)
Liquid Biopsy << Go to BM List

131. Genomics Report – November 2016131
Research Genomics (2/12)
Liquid Biopsy << Go to BM List

132. Genomics Report – November 2016132
Research Genomics (3/12)
Liquid Biopsy << Go to BM List

133. Genomics Report – November 2016133
Research Genomics (4/12)
Liquid Biopsy << Go to BM List

134. Genomics Report – November 2016134
Research Genomics (5/12)
Liquid Biopsy << Go to BM List

135. Genomics Report – November 2016135
Research Genomics (6/12)
Liquid Biopsy << Go to BM List

136. Genomics Report – November 2016136
Research Genomics (7/12)
Liquid Biopsy << Go to BM List

137. Genomics Report – November 2016137
Research Genomics (8/12)
Liquid Biopsy << Go to BM List

138. Genomics Report – November 2016138
Research Genomics (9/12)
Liquid Biopsy << Go to BM List

139. Genomics Report – November 2016139
Research Genomics (10/12)
Liquid Biopsy << Go to BM List

140. Genomics Report – November 2016140
Research Genomics (11/12)
Liquid Biopsy << Go to BM List

141. Genomics Report – November 2016141
Research Genomics (12/12)
Liquid Biopsy << Go to BM List

142. Genomics Report – November 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
142

143. Genomics Report – November 2016143
Team
143
Shubham Garg
Senior Analyst, Life Sciences
Subhabrata Pal
Lead Analyst, Life Sciences
Vikash Peesapati
Lead Analyst, Life Sciences

144. Genomics Report – November 2016144